Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas

Sue Rathe, Flavia E Popescu, James E Johnson, Adrienne L. Watson, Tracy A. Marko, Branden S Moriarity, John R. Ohlfest, David A Largaespada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Osteosarcomas are characterized by highly disrupted genomes. Although osteosarcomas lack common fusions, we find evidence of many tumour specific gene-gene fusion transcripts, likely due to chromosomal rearrangements and expression of transcription-induced chimeras. Most of the fusions result in out-of-frame transcripts, potentially capable of producing long novel protein sequences and a plethora of neoantigens. To identify fusions, we explored RNA-sequencing data to obtain detailed knowledge of transcribed fusions, by creating a novel program to compare fusions identified by deFuse to de novo transcripts generated by Trinity. This allowed us to confirm the deFuse results and identify unusual splicing patterns associated with fusion events. Using various existing tools combined with this custom program, we developed a pipeline for the identification of fusion transcripts applicable as targets for immunotherapy. In addition to identifying candidate neoantigens associated with fusions, we were able to use the pipeline to establish a method for measuring the frequency of fusion events, which correlated to patient outcome, as well as highlight some similarities between canine and human osteosarcomas. The results of this study of osteosarcomas underscores the numerous benefits associated with conducting a thorough analysis of fusion events within cancer samples.

Original languageEnglish (US)
Article number358
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Osteosarcoma
RNA Sequence Analysis
Gene Fusion
Immunotherapy
Canidae
Neoplasms
Genome
Genes
Proteins

PubMed: MeSH publication types

  • Journal Article

Cite this

Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. / Rathe, Sue; Popescu, Flavia E; Johnson, James E; Watson, Adrienne L.; Marko, Tracy A.; Moriarity, Branden S; Ohlfest, John R.; Largaespada, David A.

In: Scientific reports, Vol. 9, No. 1, 358, 01.12.2019.

Research output: Contribution to journalArticle

@article{3d57a746ee8e4633851934c38618a591,
title = "Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas",
abstract = "Osteosarcomas are characterized by highly disrupted genomes. Although osteosarcomas lack common fusions, we find evidence of many tumour specific gene-gene fusion transcripts, likely due to chromosomal rearrangements and expression of transcription-induced chimeras. Most of the fusions result in out-of-frame transcripts, potentially capable of producing long novel protein sequences and a plethora of neoantigens. To identify fusions, we explored RNA-sequencing data to obtain detailed knowledge of transcribed fusions, by creating a novel program to compare fusions identified by deFuse to de novo transcripts generated by Trinity. This allowed us to confirm the deFuse results and identify unusual splicing patterns associated with fusion events. Using various existing tools combined with this custom program, we developed a pipeline for the identification of fusion transcripts applicable as targets for immunotherapy. In addition to identifying candidate neoantigens associated with fusions, we were able to use the pipeline to establish a method for measuring the frequency of fusion events, which correlated to patient outcome, as well as highlight some similarities between canine and human osteosarcomas. The results of this study of osteosarcomas underscores the numerous benefits associated with conducting a thorough analysis of fusion events within cancer samples.",
author = "Sue Rathe and Popescu, {Flavia E} and Johnson, {James E} and Watson, {Adrienne L.} and Marko, {Tracy A.} and Moriarity, {Branden S} and Ohlfest, {John R.} and Largaespada, {David A}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-36840-z",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas

AU - Rathe, Sue

AU - Popescu, Flavia E

AU - Johnson, James E

AU - Watson, Adrienne L.

AU - Marko, Tracy A.

AU - Moriarity, Branden S

AU - Ohlfest, John R.

AU - Largaespada, David A

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Osteosarcomas are characterized by highly disrupted genomes. Although osteosarcomas lack common fusions, we find evidence of many tumour specific gene-gene fusion transcripts, likely due to chromosomal rearrangements and expression of transcription-induced chimeras. Most of the fusions result in out-of-frame transcripts, potentially capable of producing long novel protein sequences and a plethora of neoantigens. To identify fusions, we explored RNA-sequencing data to obtain detailed knowledge of transcribed fusions, by creating a novel program to compare fusions identified by deFuse to de novo transcripts generated by Trinity. This allowed us to confirm the deFuse results and identify unusual splicing patterns associated with fusion events. Using various existing tools combined with this custom program, we developed a pipeline for the identification of fusion transcripts applicable as targets for immunotherapy. In addition to identifying candidate neoantigens associated with fusions, we were able to use the pipeline to establish a method for measuring the frequency of fusion events, which correlated to patient outcome, as well as highlight some similarities between canine and human osteosarcomas. The results of this study of osteosarcomas underscores the numerous benefits associated with conducting a thorough analysis of fusion events within cancer samples.

AB - Osteosarcomas are characterized by highly disrupted genomes. Although osteosarcomas lack common fusions, we find evidence of many tumour specific gene-gene fusion transcripts, likely due to chromosomal rearrangements and expression of transcription-induced chimeras. Most of the fusions result in out-of-frame transcripts, potentially capable of producing long novel protein sequences and a plethora of neoantigens. To identify fusions, we explored RNA-sequencing data to obtain detailed knowledge of transcribed fusions, by creating a novel program to compare fusions identified by deFuse to de novo transcripts generated by Trinity. This allowed us to confirm the deFuse results and identify unusual splicing patterns associated with fusion events. Using various existing tools combined with this custom program, we developed a pipeline for the identification of fusion transcripts applicable as targets for immunotherapy. In addition to identifying candidate neoantigens associated with fusions, we were able to use the pipeline to establish a method for measuring the frequency of fusion events, which correlated to patient outcome, as well as highlight some similarities between canine and human osteosarcomas. The results of this study of osteosarcomas underscores the numerous benefits associated with conducting a thorough analysis of fusion events within cancer samples.

UR - http://www.scopus.com/inward/record.url?scp=85060397483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060397483&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-36840-z

DO - 10.1038/s41598-018-36840-z

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 358

ER -